AKR1B10 has been reported to be increased in some cancers, including HCC [12,14,15,19,23] as well as chronic liver diseases including NASH [17,18,19,24,25] and fibrosis/cirrhosis [16]. Here, AKR1B10 is linked to metabolic dysfunction-associated steatohepatitis.